Search results for "cost effectiveness"

showing 10 items of 115 documents

2019

Background Congenital Toxoplasmosis (CT) can have severe consequences. France, Austria, and Slovenia have prenatal screening programs whereas some other countries are considering universal screening to reduce congenital transmission and severity of infection in children. The efficiency of such programs is debated increasingly as seroprevalence among pregnant women and incidence of congenital toxoplasmosis show a steady decrease. In addition, uncertainty remains regarding the effectiveness of pre- and postnatal treatments. Method To identify cost-effective strategies, prenatal and neonatal screenings were compared using a decision-analytic model based on French guidelines and current knowled…

Pediatricsmedicine.medical_specialtyPregnancyMultidisciplinaryCost effectivenessbusiness.industryIncidence (epidemiology)030231 tropical medicinePrevalenceCost-effectiveness analysismedicine.diseaseToxoplasmosis3. Good health03 medical and health sciences0302 clinical medicineEpidemiologyCohortmedicine030212 general & internal medicinebusinessPLOS ONE
researchProduct

Cost-Effectiveness Analysis: Stress Ulcer Bleeding Prophylaxis with Proton Pump Inhibitors, H2 Receptor Antagonists

2012

Abstract Objectives Proton pump inhibitors (PPIs) and H2-receptor antagonists (H2RAs) present varying pharmacological efficacy in preventing stress ulcer bleeding (SUB) in intensive care units. The literature also reports disparate rates of ventilator-assisted pneumonia (VAP) as side effects of these treatments. We compared the cost-effectiveness of these two prophylactic pharmacological options. Methods We constructed a decision tree with a 60-day time horizon for patients at high risk for developing SUB, receiving either PPIs or H2RAs. For each treatment strategy, patients could be in one of three states of health: SUB, VAP, or no complication. Contemporary, clinically relevant probabilit…

Peptic Ulcermedicine.medical_specialtyMultivariate analysisDatabases FactualCost effectivenessmedicine.drug_classCost-Benefit AnalysisMEDLINEProton-pump inhibitorH2RAIntensive careInternal medicinemedicineHumanscost-effectivenessbusiness.industryHealth PolicyStress ulcerDecision TreesPublic Health Environmental and Occupational HealthProton Pump InhibitorsHealth Care CostsCost-effectiveness analysisLength of StayAnti-Ulcer Agentsmedicine.diseaseUnited StatesSurgerystress ulcer bleedingHistamine H2 AntagonistsMultivariate AnalysisGastrointestinal HemorrhagebusinessComplicationValue in Health
researchProduct

Cost-effectiveness of psychotropic polypharmacy in routine schizophrenia care. Results of the ELAN prospective observational trial

2018

Abstract Aims To analyse the costs and cost-effectiveness of psychotropic polypharmacy in comparison to antipsychotic monotherapy in patients with schizophrenia and schizo-affective disorder under real-world treatment conditions. Methods A prospective observational study including 374 adult psychiatric in-patients with schizophrenia or schizo-affective disorder was conducted. Psychotropic regimen, clinical outcomes, and quality of life were assessed before discharge and after 6, 12, 18, and 24 months. Costs and outcomes of psychotropic polypharmacy in comparison to antipsychotic monotherapy were analysed by means of mixed-effects regression models adjusted for propensity scores. Net-benefit…

Polypharmacymedicine.medical_specialtybusiness.industryCost effectivenessGeneral Neurosciencemedicine.medical_treatmentClinical study designmedicine.disease030227 psychiatry03 medical and health sciencesPsychiatry and Mental health0302 clinical medicineSchizophreniaPropensity score matchingMedicineObservational studyNeurology (clinical)businessAntipsychoticPsychiatry030217 neurology & neurosurgeryPsychopathologyNeurology, Psychiatry and Brain Research
researchProduct

The European Green Deal: New Challenges for the Economic Feasibility of Energy Retrofit at District Scale

2020

The European Green Deal proposes an epochal change in the European society by transforming environmental and climatic problems into opportunities and making sustainable and fair the European Union economic system. Radical changes will also concern urban redevelopment and energy efficiency measures in order to reduce global greenhouse gas emissions. To achieve these objectives, rules and standards, as well as financial resources and assessment tools, are needed to support both urban planning and public decision process. This paper aims to analyze the existing European programs that are applied in some European smart cities, as they constitute a valuable source of information for the developm…

Process (engineering)Cost effectivenessEnvironmental economicsCost effectivenessEnergy efficiency of buildingsOrder (exchange)Urban planningScale (social sciences)Greenhouse gasSettore ICAR/22 - Estimomedia_common.cataloged_instanceCost effectiveneEuropean Green DealBusinessEuropean unionEfficient energy usemedia_common
researchProduct

The whole story: treatment outcomes with SymbicortS

2002

Asthma is a chronic inflammatory disorder of the airways that has a considerable socioeconomic impact. Asthma management guidelines have been introduced to help provide better long-term control of asthma. Although recommended guidelines may increase the direct medication costs, the overall direct costs of asthma may be reduced due to fewer exacerbations. In addition, indirect costs due to lost productivity and mortality are reduced and patients have an improved quality of life. Inhaled corticosteroids are first-line therapy in the treatment of persistent asthma. Against this background, we have assessed the cost-effectiveness of Symbicort (budesonide and formoterol in a single inhaler), a t…

Pulmonary and Respiratory MedicineBudesonidemedicine.medical_specialtybusiness.industrymedicine.drug_classCost effectivenessInhalermedicine.diseaserespiratory tract diseasesIndirect costsQuality of lifeimmune system diseasesBronchodilatormedicineFormoterolIntensive care medicinebusinessAsthmamedicine.drugRespiratory Medicine
researchProduct

Cost-Effectiveness Analysis of Different Testing Strategies that Use Antibody Levels to Detect Chronic Hepatitis C in Blood Donors.

2016

Aim. We conducted a cost-effectiveness analysis of seven hepatitis C virus (HCV) testing strategies in blood donors. Methods. Three of the seven strategies were based on HCV diagnosis and reporting guidelines in Mexico and four were from previous and current recommendations outlined by the CDC. The strategies that were evaluated determine antibody levels according to the signal-to-cut-off (S/CO) ratio and use reflex Immunoblot (IMB) or HCV RNA tests to confirm true positive (TP) cases of chronic HCV infection. Costs were calculated from the perspective of the Mexican Institute of Social Security (IMSS). A decision tree model was developed to estimate the expected number of true positive cas…

RNA virusesDecision AnalysisPhysiologyEconomicsCost-Benefit AnalysisSocial Scienceslcsh:MedicineBlood DonorsHepacivirusmedicine.disease_causeBiochemistryHepatitis0302 clinical medicineImmune Physiology030212 general & internal medicineChroniclcsh:SciencePathology and laboratory medicinehealth care economics and organizationsMultidisciplinaryImmune System ProteinsCost–benefit analysisHepatitis C virusLiver DiseaseCost-effectiveness analysisMedical microbiologyHepatitis CHCV AntibodyInfectious DiseasesVirusesEngineering and TechnologyBlood Banks030211 gastroenterology & hepatologyPathogensInfectionManagement EngineeringResearch Articlemedicine.medical_specialtyGeneral Science & TechnologyHepatitis C virusImmunologyCost-Effectiveness AnalysisImmunoblottingChronic Liver Disease and CirrhosisMolecular Probe TechniquesAntibody levelResearch and Analysis MethodsMicrobiologyAntibodies03 medical and health sciencesChronic hepatitisHepatitis - CClinical ResearchInternal medicineparasitic diseasesmedicineHumansImmunoassaysMolecular Biology TechniquesSensitivity analysesMolecular BiologyMedicine and health sciencesBiology and life sciencesFlavivirusesbusiness.industryDecision Treeslcsh:RHepatitis C antibodyOrganismsViral pathogensProteinsHepatitis C ChronicHepatitis C AntibodiesHepatitis virusesEconomic AnalysisMicrobial pathogensHealth CareEmerging Infectious DiseasesCost Effectiveness ResearchHealth Care FacilitiesImmunologyImmunologic Techniqueslcsh:QbusinessDigestive Diseases
researchProduct

Zofenopril is a cost-effective treatment for patients with left ventricular systolic dysfunction following acute myocardial infarction: a pharmacoeco…

2013

Objective: The Survival of Myocardial Infarction Long-term Evaluation 4 Study (SMILE-4) showed the superiority of Zofenopril (Z) associated with Acetylsalicylic Acid (ASA) as respect to Ramipril (R) plus ASA in reducing the occurrence of major cardiovascular events, in patients with left ventricular dysfunction (LVD) following Acute Myocardial Infarction (AMI). The objective of this retrospective analysis was the evaluation of cost-effectiveness of Z compared to R. Methods: 771 patients with LVD and AMI were randomized, double-blind to Z 60 mg/day (n=389) or R 10 mg/day (n=382) plus ASA 100 mg/day and followed-up for 1 year. The primary study end-point was 1-year combined occurrence of deat…

RamiprilPediatricsmedicine.medical_specialtyeducation.field_of_studybusiness.industryCost effectivenessSurrogate endpointPopulationmedicine.diseaseConfidence intervalZofenoprilchemistry.chemical_compoundchemistryInternal medicinemedicineCardiologyNumber needed to treatMyocardial infarctionCardiology and Cardiovascular Medicinebusinesseducationhealth care economics and organizationsmedicine.drugEuropean Heart Journal
researchProduct

Cost-effectiveness of zofenopril in patients with left ventricular systolic dysfunction after acute myocardial infarction: a post hoc analysis of SMI…

2013

Claudio Borghi,1 Ettore Ambrosioni,1 Stefano Omboni,2 Arrigo FG Cicero,1 Stefano Bacchelli,1 Daniela Degli Esposti,1 Salvatore Novo,3 Dragos Vinereanu,4 Giuseppe Ambrosio,5 Giorgio Reggiardo,6 Dario Zava7 1Unit of Internal Medicine, Policlinico S Orsola, University of Bologna, Bologna, Italy; 2Italian Institute of Telemedicine, Varese, Italy; 3Division of Cardiology, University of Palermo, Palermo, Italy; 4University and Emergency Hospital, Bucharest, Romania; 5Division of Cardiology, University of Perugia, Perugia, Italy; 6Mediservice, Milano, Italy; 7Istituto Lusofarmaco d'Italia SpA, Peschiera Borromeo, Italy Background: In SMILE-4 (the Survival of Myocardial Infarction Long-term…

Ramiprilmedicine.medical_specialtyCost effectivenessEconomics Econometrics and Finance (miscellaneous)Populationacute myocardial infarctionramiprilchemistry.chemical_compoundInternal medicinePost-hoc analysismedicinezofenoprilMyocardial infarctioneducationcost-effectivenesshealth care economics and organizationsOriginal Researchleft ventricular dysfunctioneducation.field_of_studylcsh:R5-920business.industryHealth Policylcsh:RM1-950acetylsalicylic acidmedicine.diseaseSMILE studycost effectiveness analysis (CEA)Confidence intervalZofenoprilangiotensin-converting enzyme inhibitorsClinicoEconomics and Outcomes Researchlcsh:Therapeutics. PharmacologychemistryCardiologyNumber needed to treatMedical emergencybusinesslcsh:Medicine (General)medicine.drug
researchProduct

Cost-effectiveness of prison system development - comparison of the European countries

2020

The possibility to achieve successful resocialization of former prisoners back into society is an ongoing public debate, making it challenging for policymakers to implement prisoner rehabilitation programs capable of maintaining the public safety while allocating public funds in the most efficient way. The main aim of this study is to examine what is necessary for an investment in prison system development to be justified. The hypothesis of this study suggests that such investment can be cost-effective by reducing crime and recidivism rates in the long term by ensuring proper rehabilitation of prisoners. Accordingly, this research compares various European countries regarding their imprison…

RecidivismPublic economicsWork (electrical)Cost effectivenessmedia_common.quotation_subjectPublic debatePrisonBusinessResocializationInvestment (macroeconomics)Imprisonmentmedia_commonEuropean Integration Studies
researchProduct

Refraktiver Nutzen und inkrementelle Kosten der LASIK: Ergebnisse einer Kosten-Nutzen-Studie an zwei universitären LASIK-Zentren

2003

BACKGROUND No data is available to date on the cost effectiveness of laser in situ keratomileusis (LASIK) with regard to the German-speaking health care system. Hence we compared the clinical outcome and cost data of two German LASIK centres in respect of procedure cost effectiveness from the patient perspective. MATERIAL AND METHODS A retrospective cohort study was implemented at the University Hospitals of Mainz and Mannheim. Data on refractive outcome were obtained from the LASIK centres' patient documentation, cost data on the surgery as well as on eyeglasses etc. before and after the surgery were obtained from patient interviews. The primary endpoint of this investigation was the indiv…

Refractive errormedicine.medical_specialtyCost effectivenessbusiness.industrymedicine.medical_treatmentLASIKRetrospective cohort studyKeratomileusismedicine.diseaseUniversity hospitalhumanitiesSurgeryOphthalmologymedicineClinical endpointbusinessIncremental cost-effectiveness ratiohealth care economics and organizationsKlinische Monatsblätter für Augenheilkunde
researchProduct